Skip to main content
OpenTrials
Completed

NCT Number: NCT07113015

A Study Comparing Propranolol and Amantadine for Reducing Tremors in People With Parkinson's Disease

Parkinson's disease is a common brain disorder in older adults that causes tremors (shaking), stiffness, and problems with movement. Among these symptoms, tremors-especially those that occur at rest-can be distressing and interfere with daily life. This study aims to compare two commonly used medications, propranolol and amantadine, to determine which one is more effective and safer in reducing tremors in people with Parkinson's disease.

This clinical trial was conducted with 220 adults aged 50 to 80 years who had a confirmed diagnosis of Parkinson's disease and noticeable resting tremors. Participants were randomly assigned to receive either propranolol or amantadine for 12 weeks, while continuing their usual Parkinson's medications. Tremor severity was measured using a standard scoring tool known as the Unified Parkinson's Disease Rating Scale (UPDRS). Quality of life and side effects were also closely monitored.

The hypothesis is that propranolol would be more effective in reducing tremor severity than amantadine, though it might be associated with more side effects. Both medications were given in tablet form, twice daily, and doses were adjusted based on patient response and tolerance.

At the end of the study, both groups showed improvement, but propranolol was more effective at reducing tremors. However, it caused more side effects such as tiredness and dizziness. Quality of life improved in both groups with no major difference between them. This study may help doctors decide which medication is more suitable for treating tremors in Parkinson's disease, based on the patient's health status and side effect tolerance.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Multan Medical and Dental College

Multan, Punjab Province, 60000, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • UK Parkinson's Disease Society Brain Bank criteria [7] - Parkinson's Disease.
  • Aged between 50 and 80 years.
  • Significant (resting tremor score, defined as η ≥2 on the UPDRS Part III).
  • At least 4 weeks prior to the study, a stable regimen of PD medication.

Exclusion criteria

  • Severe bradycardia, history of asthma, or heart block (used instead of the propranolol group).
  • History of seizures or significant renal impairment (Amantadine group).
  • Cigarette smoking, pregnant or breastfeeding women.
  • Patients with MMSE < 24.
  • Participation in another clinical trial at the same time.

Treatment and study plan

Propranolol

Drug

40 mg orally twice daily, titrated up to a maximum of 80 mg/day.

Other names: Inderal, Non-selective beta-blocker

Amantadine

Drug

100 mg orally twice daily, titrated up to a maximum of 200 mg/day.

Other names: Symmetrel, NMDA receptor antagonist

Primary outcomes

  1. Change in tremor severity

    Time frame: From baseline to 12 weeks after intervention initiation

    This measure assessed the severity of resting tremor using Part III (Motor Examination) of the Unified Parkinson's Disease Rating Scale (UPDRS). Each tremor item was scored from 0 to 4, with higher scores reflecting greater severity. The change in tremor scores from baseline to week 12 was used to evaluate and compare the efficacy of propranolol and amantadine in reducing tremor severity among participants with Parkinson's disease.

Sponsors and collaborators

Lead sponsor

Multan Medical And Dental College

Other

Registry information

Official study title

Comparative Efficacy and Safety of Propranolol Versus Amantadine in Controlling Tremors in Parkinson's Disease: A Randomized Controlled Trial

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Aug 8, 2025
Registry last updated
Aug 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.